ClinicalTrials.gg
CompletedNCT03912805Updated Jul 28, 2022Results posted

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

A Phase 2 interventional study of botulinum toxin, Type A and Vehicle in Lateral Canthal Lines, LCL and Crow's Feet, sponsored by Eirion Therapeutics Inc.. Completed at 3 sites in United States. Open to female participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Eirion Therapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
Female
01

Study summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Read the detailed description

This product is being tested for its ability to reduce lateral canthal lines (LCL), also known as Crow's Feet.

02

Conditions studied

  • Lateral Canthal Lines, LCL
  • Crow's Feet
03

In context

Lead sponsor

Eirion Therapeutics Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females 25 - 65 years of age
  • minimal to moderate Crow's Feet wrinkles at rest
  • moderate to severe Crow's Feet on contraction
  • adequate vision to assess facial wrinkles in a mirror
  • willingness to refrain from products affecting skin remodeling
  • female subjects must be not pregnant and non-lactating
  • subjects should be in good general health

Exclusion criteria

Exclusion Criteria:

  • history of adverse reactions to any prior botulinum toxin treatments
  • history of vaccination or non-response to any prior botulinum toxin treatments
  • botulinum toxin treatment in the prior 6 months
  • present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
  • history of peri-ocular surgery, brow lift or related procedures
  • procedures affecting the lateral canthal region in the prior 12 months
  • application of topical prescription medication to the treatment area
  • female subjects who are pregnant or are nursing a child
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Placebo comparator
    Vehicle

    Vehicle, topical liniment, administered once at baseline

    Biological: Vehicle

  • Experimental
    ET-01 1610U

    botulinum toxin, Type A, topical liniment, administered once at baseline

    Biological: botulinum toxin, Type A

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4

    Investigators Global Assessment of the Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). Response is defined as change by at least two ordinals from Baseline to Week 4.

    Time frame: Week 4

Secondary outcomes

  1. Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit

    Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.

    Time frame: Week 1, 2, 4, 8,12,18, and 26

  2. Total Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit

    Total number of observations with a change in the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.

    Time frame: Week 1, 2, 4, 8,12,18, and 26

07

Results

Posted Jun 24, 2022

Participant flow

Participants were recruited from three medical centers between February 2019 and October 2019

Participant flow — Overall Study
MilestoneVehicleET-01 1610U
Started1919
Completed1919
Not completed00

Outcome measures

PrimaryNumber of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4

Investigators Global Assessment of the Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). Response is defined as change by at least two ordinals from Baseline to Week 4.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4
ParticipantsVehicleET-01 1610U
Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 431
SecondaryTotal Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit

Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.

Time frame:
Week 1, 2, 4, 8,12,18, and 26
Reported as:
Count of units · Observations
Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit
ObservationsVehicleET-01 1610U
Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit812
SecondaryTotal Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit

Total number of observations with a change in the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.

Time frame:
Week 1, 2, 4, 8,12,18, and 26
Reported as:
Count of units · Observations
Total Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit
ObservationsVehicleET-01 1610U
Total Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit1520

Adverse events

Collected over 26 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle0/19 (0%)0/19 (0%)6/19 (31.6%)
ET-01 1610U0/19 (0%)0/19 (0%)2/19 (10.5%)
Most frequent other events
Most frequent other events
EventVehicleET-01 1610U
Urinary Tract InfectionRenal and urinary disorders2/190/19
Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders0/191/19
Thermal BurnSkin and subcutaneous tissue disorders0/191/19
FolliculitisSkin and subcutaneous tissue disorders0/191/19
Endodontic ProcedureSurgical and medical procedures1/190/19
Oral HerpesGeneral disorders1/190/19
NephrolithiasisRenal and urinary disorders1/190/19
DyspnoeaRespiratory, thoracic and mediastinal disorders1/190/19
HordeolumEye disorders1/190/19
NasopharyngitisRespiratory, thoracic and mediastinal disorders1/190/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VehicleET-01 1610UTotal
<=18 years000
Between 18 and 65 years191938
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)VehicleET-01 1610UTotal
Female191938
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VehicleET-01 1610UTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White191938
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)VehicleET-01 1610UTotal
United States191938
IGA-C
IGA-C(units on a scale)VehicleET-01 1610UTotal
Mean3.4 ± 0.53.4 ± 0.53.4 ± 0.5
SSA-C
SSA-C(units on a scale)VehicleET-01 1610UTotal
Mean3.6 ± 0.53.5 ± 0.53.6 ± 0.5
08

Study locations

3 sites
  • Synexis, Inc.
    Pinellas Park, Florida 33781, United States
  • Yardley Dermatology Associates
    Yardley, Pennsylvania 19067, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in May 2019, 2 months.

Results were first posted in Jun 2022, 3 years 1 month after primary completion. A results delay was requested in May 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
Apr 11, 2019
StartActual
Feb 27, 2019
Primary completionActual
May 6, 2019
CompletionActual
Oct 4, 2019
Results delay requested
May 20, 2020
Results first posted
Jun 24, 2022
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03912805
Lead sponsor
Eirion Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Feb 27, 2019
Primary completion
May 6, 2019
Completion
Oct 4, 2019
Results posted
Jun 24, 2022
Last update
Jul 28, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion